Celcuity INC

Celcuity Inc. has successfully priced an upsized offering of $575 million in aggregate principal amount of 0.250% Convertible Senior Notes due 2032, with net proceeds intended for debt repayment and general corporate purposes.

Celcuity Inc. announced detailed Phase 3 VIKTORIA-1 trial results for gedatolisib, showing a significant improvement in progression-free survival for advanced breast cancer patients.

Celcuity Inc. announces the appointment of Charles (Chip) R. Romp to its Board of Directors, increasing the board size to eight members.

Celcuity Inc. announced the approval of its 2026 Stock Incentive Plan and Amended and Restated 2017 Employee Stock Purchase Plan by stockholders at the 2026 Annual Meeting.

Celcuity announced that its Phase 3 VIKTORIA-1 trial met its primary endpoint, showing improved progression-free survival in PIK3CA mutant breast cancer patients.

Celcuity Inc. announced its fourth quarter and full year 2025 financial results, alongside a corporate update highlighting FDA Priority Review for gedatolisib and positive Phase 3 clinical trial data.

Celcuity Inc. reported a widened net loss in Q1 2026 due to increased R&D and commercialization expenses, while advancing its lead drug candidate gedatolisib with positive clinical trial results and an FDA Priority Review.

Celcuity Inc. announced positive Phase 3 clinical trial results for gedatolisib in HR+/HER2advanced breast cancer and significantly bolstered its liquidity with over $286 million in new financing.

Celcuity Inc. announced positive topline Phase 3 VIKTORIA-1 data for gedatolisib in breast cancer and secured over $286 million in new capital to extend its operational runway through 2027.

Celcuity Inc. announces its Q1 2025 financial results and provides updates on its ongoing clinical trials, including the expected timing of topline data for VIKTORIA-1 and CELC-G-201.

Celcuity Inc. announced its third quarter 2024 financial results, highlighting increased research and development spending and progress in its clinical trials for gedatolisib.

Celcuity Inc. reported a net loss for the second quarter of 2024, while also advancing its clinical programs and securing significant funding.

Celcuity Inc. announced the FDA's acceptance of its New Drug Application for gedatolisib with Priority Review, targeting HR+/HER2advanced breast cancer, following strong Phase 3 clinical trial results.

Celcuity Inc.'s 10-K filing provides a detailed overview of its capital stock structure, outstanding warrants, and measures in place to deter potential takeovers as of December 31, 2024.

Celcuity Inc.'s 10-K filing outlines its capital structure, including common and preferred stock, warrants, and compliance with securities regulations.

Baker Bros. Advisors Lp and 3 others reported changes in beneficial ownership of Celcuity Inc. common stock on July 14, 2026.

Director Polly A. Murphy transferred 14,048 stock options to a trust for which she and her spouse serve as trustees.

Director Richard E. Buller reported a transfer of 12,503 stock options to a family trust on June 10, 2026.

Celcuity Inc. director Polly A. Murphy was granted 1,530 restricted stock units as part of annual compensation.

Director David Dalvey acquired 1,530 restricted stock units in Celcuity Inc. as part of a standard equity compensation grant.

Director Charles R. Romp acquired 1,530 restricted stock units in Celcuity Inc. as part of a standard equity compensation grant.

Celcuity Inc. has issued its 2026 proxy statement detailing proposals for director elections, executive compensation, and new equity incentive plans.

Celcuity Inc. has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.

Celcuity Inc. is holding its 2025 Annual Meeting of Stockholders on May 13, 2025, to vote on key proposals including the election of directors, ratification of the accounting firm, executive compensation, and a significant increase to the stock incentive plan.

Celcuity Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Celcuity Inc. is asking stockholders to approve an amendment to its Certificate of Incorporation to increase the authorized number of common stock shares from 65,000,000 to 95,000,000 at a special meeting on October 7, 2024.

Celcuity Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Baker Bros. Advisors LP and its affiliates have filed an amendment to their Schedule 13D, reporting a reduction in their beneficial ownership of Celcuity Inc. common stock to 9.99% and intending to transition to Schedule 13G filings.

Baker Bros. Advisors increased its beneficial ownership limitation in Celcuity Inc. from 4.99% to 19.99% for certain prefunded warrants, signaling potential for increased influence.

Growth Equity Opportunities 18 VGE and affiliated entities have updated their beneficial ownership in Celcuity Inc. to 6.3% following recent share distributions and sales.

New Enterprise Associates (NEA) affiliated entities and individuals have reduced their beneficial ownership in Celcuity Inc. to 8.1% due to increased outstanding shares and recent sales.

Baker Bros. Advisors and its affiliates have significantly increased their beneficial ownership in Celcuity Inc. to 18.9% through a series of strategic investments including pre-funded warrants, convertible notes, and open market purchases.

Baker Bros. Advisors LP and affiliated entities have filed a Schedule 13G, reporting beneficial ownership of 9.99% of Celcuity Inc.'s common stock.

RTW Investments, LP and Roderick Wong have reported beneficial ownership of 6.3% of Celcuity Inc. common stock as of March 31, 2026.

Avoro Capital Advisors LLC and Behzad Aghazadeh have reported a beneficial ownership of 6.72% in Celcuity Inc., holding 3,111,111 shares for investment purposes.

Soleus Capital Management and related entities, including Guy Levy, report a combined beneficial ownership of 3.9% of Celcuity Inc. common stock.

Biotechnology Value Fund and its affiliates reported a combined 1.6% passive beneficial ownership stake in Celcuity Inc. as of September 30, 2025.

Brian F. Sullivan, a key insider, has increased his beneficial ownership in Celcuity Inc. to 9.1% of the common stock.